Kala Pharmaceuticals Reports EYSUVIS Coverage on UnitedHealthcare Commercial and Cigna Medicare

Mar 9, 2022 By MarketDepth

Business Headlines Healthcare Investing What's Hot

Cancer Research

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) has reported that UnitedHealthcare has added EYSUVIS as a covered brand on its commercial formularies effective March 2022.  EYSUVIS has covered 118 million lives or 70% of all commercial lives.  “Today’s announcement marks significant progress toward our goal of expanding access to EYSUVIS for the millions of people who suffer from dry eye disease, including dry eye flares,” said Todd Bazemore, President and Chief Operating Officer of Kala Pharmaceuticals. “We look forward to continuing to engage with other commercial and Medicare Part D health plans as we execute on our goal of providing broad market access to EYSUVIS for eye care professionals and their patients.”

Preferred Brand

Kala reported that Cigna Medicare has added EYSUVIS as a preferred brand effective on February 2022, adding an additional 1.9 million Medicare lives.

Commercially Available

EYSUVIS has become commercially available since January 2021 as the first and only FDA-approved medicine for short-term treatment of the signs and symptoms of dry eye disease.